|
| Status |
Public on Dec 22, 2016 |
| Title |
Breast tumor_ Control 2 |
| Sample type |
RNA |
| |
|
| Source name |
Primary breast tumor not treated
|
| Organism |
Homo sapiens |
| Characteristics |
agent: DMSO
tissue: Breast cancer
|
| Treatment protocol |
A daily oral treatment with sirolimus (Rapamune) or control solution (DMSO) was applied (60 days).
|
| Growth protocol |
Primary triple-negative breast tumor (from a BRCA1 mutation carrier) orthotopically engrafted in immunocompromised mice was monitored 2 to 3 times per week.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol extraction of total RNA was performed according to manufacturer's instructions.
|
| Label |
Biotin
|
| Label protocol |
FL-Ovation cDNA Biotin Module V2 from NuGen Technologies Inc.
|
| |
|
| Hybridization protocol |
Affymetrix GeneChip Expression Analysis Technical Manual (P/N 702232 Rev 2).
|
| Scan protocol |
Affymetrix GeneChip Expression Analysis Technical Manual (P/N 702232 Rev 2).
|
| Data processing |
The data were analyzed with Partek Genomics Suite using Affymetrix default analysis settings and global scaling as normalization method.
|
| |
|
| Submission date |
Jul 27, 2012 |
| Last update date |
Dec 23, 2016 |
| Contact name |
Miguel Angel Pujana |
| E-mail(s) |
mapujana@iconcologia.net
|
| Phone |
0034932607463
|
| Organization name |
Institut Catala d'Oncologia IDIBELL
|
| Lab |
ProCURE
|
| Street address |
Gran Via 199
|
| City |
Barcelona |
| ZIP/Postal code |
08908 |
| Country |
Spain |
| |
|
| Platform ID |
GPL13667 |
| Series (2) |
| GSE39691 |
Expression data from a triple-negative BRCA1-mutated ortho-xenograft treated with sirolimus |
| GSE39694 |
Expression data from orthotopic tumors and the MCF7 and HCC1937 breast cancer cell lines |
|
